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Micelles composed of amphiphilic copolymers linked to a radioactive element are used in nuclear 
medicine predominantly as a diagnostic application. A relevant advantage of polymeric micelles in 
aqueous solution is their resulting particle size, which can vary from 10 to 100 nm in diameter. In this 
review, polymeric micelles labeled with radioisotopes including technetium (99mTc) and indium (111In), 
and their clinical applications for several diagnostic techniques, such as single photon emission computed 
tomography (SPECT), gamma-scintigraphy, and nuclear magnetic resonance (NMR), were discussed. 
Also, micelle use primarily for the diagnosis of lymphatic ducts and sentinel lymph nodes received special 
attention. Notably, the employment of these diagnostic techniques can be considered a significant tool for 
functionally exploring body systems as well as investigating molecular pathways involved in the disease 
process. The use of molecular modeling methodologies and computer-aided drug design strategies can 
also yield valuable information for the rational design and development of novel radiopharmaceuticals.
Uniterms: Radiopharmaceuticals/development. Polymeric micelles/diagnostic application. Radioisotopes. 
Imaging diagnostic agents. Diagnostic techniques.
Micelas poliméricas compostas de copolímeros ligadas a um elemento radioativo são utilizadas em 
Medicina Nuclear com aplicação predominantemente diagnóstica. A vantagem relevante da utilização 
de micelas poliméricas em solução aquosa é o tamanho de suas partículas, as quais podem variar de 10 
a 100 nm de diâmetro. Neste trabalho de revisão são apresentadas micelas poliméricas marcadas com 
radioisotopos, como tecnécio-99m (99mTc) e índio-111 (111In), assim como suas aplicações clínicas em 
técnicas de diagnóstico como Tomografia por emissão de Fóton Único (Single photon Emission Computed 
Tomography - SPECT), cintilografia, e Ressonância Magnética Nuclear (RMN). Neste contexto, sua 
aplicação em diagnóstico de sistema linfático e linfonodo sentinela recebe atenção especial. O emprego 
de técnicas de diagnóstico pode ser considerado uma ferramenta importante para a exploração de 
sistemas no organismo humano assim como para a investigação de caminhos moleculares envolvidos 
nos processos de diversas doenças. O uso de metodologias de modelagem molecular e estratégias de 
desenvolvimento de fármacos assistidas computacionalmente também pode fornecer informações valiosas 
para o planejamento e o desenvolvimento racional de novos radiofármacos.
Unitermos: Radiofármacos/desenvolvimento. Micelas poliméricas/aplicação diagnóstica. Radioisótopos. 
Agentes para imagens em diagnóstico. Técnicas de diagnóstico.
INTRODUCTION
In recent decades, technological and scientific ad-
vances in molecular imaging have allowed the identifica-
tion and characterization of the components, processes, 
dynamics and therapy of diseases at a molecular level. 
The use of new molecules, radiopharmaceuticals or 
contrast agents, allied to traditional imaging tools, has 
enabled visualization of tissular events and disclosure 
of the specific molecular targets in the body which are 
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responses during disease progression (Pan et al., 2009; 
Wong, Kim, 2009).
The fields of diagnostic medicine by imaging meth-
ods include the use of positron-emitting (particulate β+ 
radiation) and gamma-emitting (γ radiation) radioactive 
materials in techniques such as computed tomography 
(CT) associated to positron emission tomography (PET) 
and single photon emission computed tomography 
(SPECT), or the use of contrast agents in CT, magnetic 
resonance imaging (MRI), and ultrasonography (U.S.) 
(Hamoudeh et al., 2008).
In all of the above-mentioned methods, clinical 
diagnosis requires a certain intensity of signal emitted 
from the area of interest so that the difference between the 
structure under observation and the surrounding tissues 
can be recorded. In this context, radiopharmaceuticals and 
contrast agents are employed for their ability to adsorb 
these signals (radiation) more strongly than neighboring 
tissues (Hamoudeh et al., 2008).
To achieve the necessary concentration of a radio-
pharmaceutical at the desired site, several carriers such as 
nanoparticles, liposomes, and microspheres, for example, 
have been proposed (Grallert, 2006; Torchilin, 1999). 
Micelles, which are colloidal particles formed by am-
phiphilic moieties, number among the carriers exploited, 
particularly due to their physicochemical properties of 
easy handling and suitable pharmacokinetic characteristics 
(Kwon, Kataoba, 1995; Lasik, 1992).
In this sense, the particle size, charge and surface 
properties of micelles can be modified by adding new 
compounds to the mixture of amphiphilic agents or 
by changing the preparation method in order to target 
distinct types of in vivo release profiles. Some micelles, 
upon exposure of their outer surface to the aqueous en-
vironment. have low reactivity to blood and tissue com-
ponents, enabling them to remain in circulation for long 
periods of time without being recognized by proteins and/
or phagocytic cells. This longevity is a highly relevant 
feature of micelles as drug carriers since it allows their 
gradual accumulation in specific clinically important 
areas (Torchilin, 2002).
However, there is growing interest in nuclear 
medicine images of the lymphatic system, also known 
as lymphoscintigraphy, due to a recent histopathological 
validation of the sentinel lymph node (SLN) concept in 
patients with surface cancers such as malignant melanoma 
and breast cancer (Kowalsky, Falen, 2004; Wilhelm, Mi-
jnhout, Franssen, 1999). In the latter case, the SLN biopsy 
procedure has gradually replaced the axillary lymph node 
dissection technique (Sener, 2004; Vera, Wallace, Hoh, 
2001). Moreover, the SLN concept has also been applied 
to the treatment of endometrial cancer in an effort to avoid 
complete systematic lymphadenectomy whenever possible 
(Nikura et al., 2004).
In general, lymph nodes are an early site for cancer 
spread (metastasis) and local spread of infectious diseases 
such as acquired immunodeficiency syndrome (AIDS). 
The SLN in particular, is the first lymph node subject to 
direct drainage from the primary lesion site of the tumor, 
being more likely to contain metastatic tumor cells than 
other lymph nodes in the same region. Usually, the prog-
nostic significantly improves when cancer cells are not 
found in the SLN by pathological examination (Kowalsky, 
Falen, 2004; Goins, Phillips, 2001).
Radiopharmaceuticals such as technetium (99mTc) 
sulfur colloid, 99mTc filtered sulfur colloid, 99mTc-albumin 
colloid, 99mTc-antimony trisulfide colloid, and 99mTc-human 
serum albumin, are currently used for detecting SLNs 
(Sener et al., 2004; Vera, Wallace, Hoh, 2001; Nieweg et 
al., 1999). The colloidal forms, especially 99mTc filtered 
sulfur colloid, have slower rate of clearance from the site 
of injection. Thus, the scattering of radiation from the ap-
plication site can mask the SLN, which is often located 
only a few inches away. Radiopharmaceuticals without 
affinity for lymph nodes, such as albumin colloid labeled 
with 99mTc, can circulate through the lymphatic system 
over long periods, impairing the identification of the SLN 
(Vera, Wallace, Hoh, 2001).
In this review, distinct preparation methods of 
polymeric micelles, and their applications as radiophar-
maceuticals, are discussed, outlining the mapping of the 
lymphatic system, SLN, and tumors. Additionally, molecu-
lar modeling and computer-aided drug design (CADD) 
strategies for the rational design of radiopharmaceuticals 
are focused.
NANOTECHNOLOGY
Nanotechnology is a field of research at a crossroads 
with biology, chemistry, physics, engineering, and medi-
cine. According to the National Nanotechnology Initiative 
(NNI; http://www.nano.gov), nanotechnology refers to 
the understanding and control of matter at dimensions 
between approximately 1 and 100 nm (nanoscale), where 
unique phenomena enable novel applications. Unusual 
physical, chemical, and biological properties can emerge 
in materials at the nanoscale. These properties may dif-
fer in important ways compared to the properties of bulk 
materials and single atoms or molecules. Considering this 
size range in perspective, a small molecule, a virus, a bac-
terium, and the cross section of a human hair are around 
1 nm, 100 nm, 1000 nm and 100,000 nm, respectively 
Polymeric micelles and molecular modeling applied to the development of radiopharmaceuticals 3
(Hamoudeh et al., 2008; Alexis et al., 2008).
Nanotechnology generally refers to structures that 
are up to several hundred nanometers in size, and are 
developed by top-down or bottom-up engineering of 
individual components based on a rational design. The 
resulting nanomaterials may have functional properties 
that are conferred through the precise assembly of indi-
vidual components but not by the individual components 
alone. Nanomaterials have a large surface area to volume 
ratio and their physicochemical properties, such as friction 
and interaction with other molecules, are distinct from 
equivalent materials at a larger scale (Alexis et al., 2008; 
Ferrari, 2005).
The most common application of nanotechnology 
in medicine has been in the development of both new 
therapeutic agents and distinct imaging modalities for 
diagnosis. In the first case, nanocarriers can mainly im-
prove solubility, the pharmacokinetic profile of drugs and 
provide site-specificity. For diagnostic imaging, the main 
contribution is site-specificity. Examples of nanocarrier 
systems include polymeric micelles, dendrimers, nano-
capsules, liposomes, nanoparticles based on nucleic acid, 
and viral nanoparticles (Ferrari, 2005). 
The nanocarrier or drug delivery systems have the 
potential to improve the therapeutic index of currently 
used drugs, and may increase their efficacy, reduce their 
toxicity or enhance their bioavailability. They can also aid 
the solubility and stability of drugs, allowing the devel-
opment of novel chemical entities which were formerly 
rejected in pre-clinical or clinical phases due to their inap-
propriate pharmacokinetics or biochemical profile (Wong, 
Kim, 2009; Rangel-Yagui, 2007). Moreover, nanocarrier 
systems can facilitate the development of multifunctional 
polymeric systems for targeted drug delivery (Nasongkla 
et al., 2006), combination therapy (Larina et al., 2005), 
or systems for use in therapy or diagnosis (Alexis et al., 
2008).
The first nanocarrier system was a liposome devel-
oped approximately 40 years ago (Bangham, Standish, 
Watkins, 1965), also reported by Torchilin (2005). The last 
two decades, however, has seen a significant improvement 
in the development of colloidal carriers in the nanoscale 
size range that have distinct chemical and physicochemical 
properties for application as drug vectors. More recently, 
the U.S. Food and Drug Administration (FDA) approved 
the first generation of nanoparticle formulations such as 
Feridex (Wang, Hussain, Krestin, 2001) for diagnostic 
applications and Abraxane (Green et al., 2003) and Doxil 
(Ellerhorst et al., 1999) for cancer therapy.
Polymeric micelles represent the most effective 
class of nanocarrier systems for diagnostic applications 
and tumor chemotherapy (Alexis et al, 2008). Several 
types of micelles have been proposed as delivery ve-
hicles for drugs including paclitaxel (Zhang, Jackson, 
Burt, 1996) and doxorubicin (Yokoyama et al., 1990) in 
cancer therapy as well as for diagnostic agents, such as a 
complex of gadolinium with a chelating agent (diethyl-
enetriaminepenta-acetic acid, Gd-DTPA) (Trubetskoy et 
al., 1996). In addition, polymeric micelles have also been 
used in radiopharmacy applications to aid the diagnostic 
procedure for lymphatic pathways and for detecting the 
SLN (Hamoudeh et al., 2008).
In this context, a recent advance in pharmaceuti-
cal technology applied to radiopharmacy involves the 
search for new carrier agents on the nanoscale (10-9 m) 
such as liposomes, and on the microscale (10-6 m), such 
as polymeric microcapsules. Nanomedicine, which is the 
medical application of nanotechnology, is set to exploit 
this information for developing new approaches in mo-
lecular diagnosis, tumor imaging and targeted therapies 
(Hamoudeh et al., 2008; Alexis et al., 2008).
PHYSICOCHEMICAL PROPERTIES OF 
POLYMERIC MICELLES
Surfactants are amphiphilic molecules composed of 
a hydrophilic or polar moiety known as the “head”, and 
a hydrophobic or nonpolar moiety known as the “tail” 
(Israelachvili, 1992). Surfactants in aqueous solution 
can display distinct kinds of behavior depending on their 
concentration. When surfactant molecules are dissolved 
in aqueous solution at concentrations above the critical 
micelle concentration (CMC), they spontaneously form 
aggregates known as micelles, in which the hydrophilic 
head regions are in contact with the surrounding solvent 
(water), sequestering the hydrophobic tail regions in the 
micelle centre thus minimizing their contact with water 
(Torchilin, 2007; Trubetskoy, 1999; Chevalier, Zemb, 
1990).
The formation of micelles in water results from a 
delicate balance of intermolecular forces, including van 
der Waals, electrostatic, steric, hydrophobic, and hydrogen 
bonding interactions (Rangel-Yagui, Pessoa-Jr, Tavares, 
2005; Israelachvili, 1992; Tanford, 1980).
Micellar systems have particular significance in 
pharmacy given their ability to increase solubility of spar-
ingly soluble drugs and to improve their bioavailability, as 
well as to reduce toxicity and other harmful side effects, 
enhance permeability through biological barriers, and 
provide significant changes in biodistribution. The lower 
the CMC value of a given surfactant, the more stable are 
its micelles. This is especially important from a pharma-
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cological point of view, since upon dilution with a large 
volume of blood, considering intravenous administration, 
only micelles of surfactants with low CMC value remain, 
while micelles from surfactants with high CMC value may 
dissociate into monomers and their content precipitate in 
the blood (Rangel-Yagui, Pessoa-Jr, Tavares, 2005). The 
use of certain amphiphilic molecules such as polymeric 
types may also increase the plasma half-life of micelles 
upon intravenous administration. Moreover, specific li-
gands can be chemically attached to the micellar surface, 
and the drug release at the site of action, directly from 
within the micelles to the target (tissue/cells), should pro-
vide an increase in drug effectiveness, whereas the stability 
of micelles can also contribute to a reduction in toxicity 
(Torchilin, 2006, 2007).
According to Kabanov et al. (1992), the ideal self-
assembling drug delivery system should spontaneously 
form from drug molecules, carrier components and tar-
geting moieties, and should have the following specific 
properties: (i) aggregate size of around 10 nm in order to 
enable them to penetrate various tissues and even cells; 
(ii) be stable in vivo for a sufficiently long period of time 
without causing any undesirable biological reactions; (iii) 
release the drug upon contact with target tissues/cells; and, 
(iv) the components of the carrier (loader or surfactant 
molecules) should be easily removed from the body when 
the therapeutic function has been achieved.
The use of polymeric micelles as a drug delivery 
system deserves special attention. Polymeric micelles are 
formed from copolymers consisting of both hydrophilic 
and hydrophobic monomer units (Torchilin, 2002). Hence, 
unlike homopolymers, which are formed by identical 
monomer units, copolymers present two kinds of mono-
mers differing in solubility. In Figure 1, a schematic 
representation of the mechanism of polymeric micelle 
formation is shown. Copolymers such as AB or ABA can 
spontaneously assemble into a number of supramolecular 
structures of different morphology in aqueous solution. 
Also, copolymers such as AB (amphiphilic block copoly-
mers) whose length of the hydrophilic block exceeds the 
length of the hydrophobic block, generally form spherical 
micelles in aqueous medium (Trubetskoy, 1999). The mi-
cellar core corresponds to hydrophobic blocks whereas the 
shell region, which is in contact with the aqueous solution, 
consists of hydrophilic blocks (Kwon, Kataoka, 1995).
Micelles formed from copolymers such as AB and 
ABA are of greater interest pharmacologically. The hy-
drophilic group commonly consists of polyethylene oxide 
(PEO, also known as polyethylene glycol, PEG) chains, 
a polymer that is highly soluble in water (Kwon, 1998). 
The main advantage of copolymers containing PEO head 
groups is their low toxicity (Magnusson, Olson, Nyberg, 
1986). Moreover, the PEO coating efficiently prevents 
opsonization and subsequent recognition by macrophages 
of the reticuloendothelial system (RES), allowing the 
micelles to circulate longer and deliver drugs more ef-
fectively to the desired sites (Rapoport, 2007; Soo et al., 
2002; Trubetskoy, Torchilin, 1995).
The low CMC values associated with the forma-
tion of polymeric micelles confer high pharmacokinetic 
stability. Micelles having high CMC values when subject 
to extreme dilution in circulating blood can dissociate into 
monomers before reaching the target site. Conversely, the 
slow dissociation of kinetically stable polymeric micelles 
allows them to retain their integrity and drug content 
in blood circulation above or even below the CMC for 
some time, reaching the target site before decaying into 
monomers. (Rangel-Yagui, Pessoa Junior, Tavares, 2005; 
Torchilin, 2006).
As previously mentioned, a very important property 
of polymeric micelles is their size, typically from 10 to 
100 nm, occupying the gap between drug carriers such 
as individual macromolecules (albumin, dextran, and 
antibodies) with a size less than 10 nm, and nanocarriers 
such as liposomes and microcapsules measuring 100 nm 
or larger (Rangel-Yagui, Pessoa Junior, Tavares, 2005; 
FIGURE 1 - Formation of polymeric micelles from different 
types of amphiphilic block copolymers (Adapted from: 
Torchilin, 2001).
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Trubetskoy, 1999). This is relevant for selected drug 
administration routes such as percutaneous lymphatic 
delivery, or for extravasation into solid tumors. From a 
practical standpoint, micellar preparations are easy to 
prepare, handle, and sterilize by filtration, mainly due to 
their small size (Trubetskoy, 1999).
CLINICAL APPLICATIONS
Clinical applications of polymeric micelles as carriers 
of radiopharmaceuticals and diagnostic (contrast) agents are 
based upon the unique properties of these supramolecular 
assemblies in aqueous solution. Radiopharmaceuticals and 
diagnostic agents serve to delineate body systems, organs 
and tissues on the images upon oral or parenteral adminis-
tration. Most commonly used radiopharmaceuticals for two 
important imaging modalities present chelated radioactive 
metals in their composition, such as indium (111In) or tech-
necium (99mTc) for scintigraphy, and organic iodine (123I) for 
CT. Conversely, contrast agents, which are generally used 
in MRI, do not have a radioactive element in their structure, 
but instead contain chelated paramagnetic metals, such as 
gadolinium (Gd) (Hamoudeh et al., 2008; Torchilin, 1999; 
Trubetskoy, 1999).
Contrast agents, also referred to as imaging enhanc-
ers, were included in this review of radiopharmaceuticals 
given their relevance in terms of clinical application, as 
diagnostic agents, and in academic research as a basis 
for developing novel non-invasive cellular imaging tech-
niques, for example.
The overwhelming majority of radiopharmaceuti-
cals currently used in clinical medicine are low-molecular 
weight compounds having the above-mentioned chemical 
moieties. However, there are some applications in clinical 
imaging which require the use of high-molecular weight 
radiopharmaceuticals or particulate contrast agents. They 
may be needed for example in order to overcome the 
inconvenience of rapid disappearance of low-molecular 
weight radiopharmaceuticals into interstitial space, impair-
ing the proper delineation of the vasculature or lymphatics 
during surgical procedures aided by imaging agents. The 
three most obvious examples of the use of particulate 
radiopharmaceuticals are blood pool imaging by long-
circulating particulate carriers, tumor accumulation as a 
result of circulation longevity, and accumulation of par-
ticulates in lymph nodes after subcutaneous administration 
(Alexis et al., 2008, Torchilin, 1999; Trubetskoy, 1999). 
Most of these applications have clinical significance 
during detection and staging of distinct types of human 
cancers (Hamoudeh et al., 2008), as well as for diagnosing 
certain heart conditions (Trubetskoy, 1999).
The use of polymeric micelles as carriers of radio-
pharmaceuticals and diagnostic agents can yield great 
clinical benefits in all three major imaging modalities 
(scintigraphy, CT, MRI). For each of these specific ap-
plications, certain requirements related to the diagnostic 
agent should be taken into account. The most important 
is certainly the presence of a protective polymeric layer 
on the particles to prevent interaction with RES cells. In 
this case, the size of resulting particulates is also of prime 
importance (Trubetskoy, 1999).
POLYMERIC MICELLES CONTAINING 
AMPHIPHILIC POLYCHELATORS AS 
DIAGNOSTIC AGENTS
As previously mentioned, clinical diagnostic imag-
ing requires that a certain intensity of signal (irradiation) 
from an area of interest is achieved in order to differentiate 
structures under observation from surrounding tissues. The 
efficacy of micelles as radiopharmaceuticals or contrast 
agents could be improved by increasing the quantity of 
carrier-associated reporter metal (such as 111In or Gd), thus 
enhancing signal intensity (Torchilin, 1999). 
Torchilin and Trubetskoy (1994) tried to tackle this 
issue by using so-called amphiphilic chelating polymers. 
These authors experimentally designed a new family of 
soluble single-terminus modified polymers containing 
multiple chelating groups suitable for incorporation into 
liposomes and micelles. The approach was based upon 
the use of carbobenzoxy (CBZ)-protected polylysine (PL) 
with a free terminal amino-group, which is derivatized into 
a reactive form with subsequent deprotection and incor-
poration of diethylenetriaminepentaacetic acid (DTPA) 
residues, and was initially suggested as a heavy metal 
label in proteins and antibodies (Torchilin, 1999; Slinkin, 
Kilbanov, Torchilin, 1992).
Considering the PL N-terminus modification 
chemistry, the pathway for the synthesis of amphiphilic 
polychelator N,α-(DTPA-polylysyl)glutaryl phosphati-
dyl ethanolamine (DTPA-PL-NGPE) was developed. 
DTPA-PL-NGPE easily incorporates into the micelle 
and increases the number of metal atoms attached to a 
single lipid anchor. Thus, the number of bound reporter 
metal atoms per single carrier particle can be increased 
(Torchilin, 1999).
Micelles formed by self-assembled amphiphilic 
polymers such as PEO- phosphatidyl ethanolamine (PEO-
PE) can also be labeled with amphiphilic PL-based che-
lates carrying diagnostically important metal ions, such 
as 111In and Gd (Trubetskoy, Torchilin, 1996), and the 
final preparations are relatively stable in vivo. In case of 
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the MRI modality, it is especially important that chelated 
metal atoms are directly exposed to the water environment, 
which improves the relaxivity of the paramagnetic ions 
and leads to the corresponding enhancement of the vesicle 
contrast properties (Torchilin, 1999).
The presence of PEO in the vicinity of paramagnetic 
atoms helps reduce the total dose of an administrated metal 
due to the increase in the relaxivity of the particulate. Ad-
ditionally, upon subcutaneous administration, micelles 
rapidly move via the lymphatic pathway, mostly staying 
within lymph fluid rather than accumulating in the nodal 
macrophages because of the protective effect of the surface 
PEG fragments (Torchilin, 1999).
POLYMERIC MICELLES LABELED WITH 
PARAMAGNETIC METALS FOR MRI
The delivery of therapeutics by micelles is a well-
developed and evolved field (see refs Rangel-Yagui, Pes-
soa Junior, Tavares, 2007; Rangel-Yagui, Pessoa Junior, 
Tavares, 2005; Kwon, 1995 for examples). Besides the 
practical value for diagnosis itself, this area is relevant 
for the visualization of the exact sites of drug carrier de-
position within the body with extraordinary anatomical 
resolution (Torchilin, 1999). 
Chelated paramagnetic metal moieties (Gd, Mn 
or Dy aqueous ions) represent the major interest for de-
signing contrast agents applied to diagnosis using MRI 
(Trubetskoy et al., 1996). Mixed micelles obtained from 
monoolein and taurocholate with Mn-mesoproporphyrin, 
for example, seem to be a potential oral hepatobiliary 
contrast agent for MRI (Schmeidl et al., 1995). Chelated 
metal ions frequently have a hydrophilic character. The 
complex of DTPA-Gd3+, for example, presents a water 
molecule bound directly to the metal coordination sphere 
(Lauffer, 1990). Thus, in order to be incorporated into mi-
celles, such structures must acquire an amphiphilic nature 
(Torchilin, 1999).
Several chelating probes with an amphiphilic na-
ture were previously developed for liposome membrane 
incorporation studies, such as DTPA-PE (Grant, Karlik, 
Florio, 1989), DTPA-stearylamine (DTPA-SA) (Kabalka 
et al., 1989), and amphiphilic acylated paramagnetic com-
plexes of Mn and Gd (Unger et al., 1994). In these agents, 
a hydrophilic chelating residue is covalently linked to a 
hydrophobic (lipid) chain. The lipid part of the molecule 
can be anchored either in the liposome bilayer or the mi-
celle’s hydrophobic core while a more hydrophilic chelate 
is placed on the liposome surface or hydrophilic shell of 
the micelle. Incorporation of radioactive ion chelate allows 
the investigation of pharmacokinetic parameters in vivo, 
including blood half-life and biodistribution (Torchilin, 
1999).
Amphiphilic chelating probes such as paramagnetic 
Gd-DTPA-PE and radioactive 111In-DTPA-SA were incor-
porated into PEO(5 kDa)-PE micelles and used in vivo for 
MRI and scintigraphy techniques. The main feature of this 
kind of micelle useful in diagnostic imaging applications 
is their size (20 nm in diameter) (Rangel-Yagui, Pessoa 
Junior, Tavares, 2007). 
Furthermore, it is not possible to prepare liposomes 
smaller than 70-100 nm owing to lipid bilayer curvature 
limitations (Enoch, Strittmatter, 1979). For some diagnos-
tic applications, such as percutaneous lymphography, the 
administration of diagnostic particulates of a significantly 
smaller size is required (Torchilin, 1999). An experiment 
using polystyrene nanospheres showed that particulate 
uptake in the primary lymph node after subcutaneous 
injection is drastically increased when nanospheres hav-
ing a diameter of less than 100 nm were used (Davis et 
al., 1993). 
POLYMERIC MICELLES FOR DIAGNOSIS OF 
SLN AND LYMPHATIC SYSTEM
The optimum size of the colloidal particles remains 
an unresolved issue. However, the behavior of colloids 
injected interstitially depends on their particle size. Ra-
diopharmaceutical colloidal preparations should have par-
ticulates with uniform size below 100 nm, which are able 
to travel from the injection site and reach the lymphatic 
ducts and lymph nodes. Very large particles fail to migrate 
and tend to remain in the interstitium at the injection site 
whereas particles smaller than 4-5 nm travel so quickly 
that only a fraction is retained in the first (sentinel) lymph 
node (Nieweg et al., 1999; Henze et al., 1982; Ege, 1976). 
In addition, excessively small particles will likely cross 
the endothelium and promptly enter into blood circulation 
(Nieweg et al., 1999).
The most common radiopharmaceutical employed 
as an SLN localization agent is 99mTc-labeled sulfur col-
loid. Other radiopharmaceuticals used for this purpose 
have also been reported, including 99mTc-labeled dextran, 
99mTc hydroxyethyl starch (HES), 99mTc human serum 
albumin (HSA) and several labeled colloids, such as 198Au-
colloid, 99mTc stannous phytate, 99mTc-antimony trisulfide 
colloid (ATC), 99mTc rhenium colloid and 99mTc colloidal 
albumin (Wilhelm, Mijnhout, Franssen, 1999). 
However, none of these entirely fulfill the desired 
criteria of an ideal imaging agent, and the search for an 
optimal nanoparticulate radiopharmaceutical continues 
(Jain, Dandekar, Patravale, 2009).
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Trubetskoy and Torchilin (1995) synthesized a series 
of PEO-PE conjugates with molecular weights of 2 kDa, 5 
kDa and 12 kDa. Micelles of different sizes were formed 
in an aqueous environment. Also, after serially diluting 
(up to 1 mmol/mL) samples of PEO(5 kDa)-PE no dis-
sociation into individual polymeric chains was observed, 
confirming the stability of the micelles and indicating low 
values of CMC. They showed that PEO-PE micelles can 
efficiently incorporate some sparingly soluble and amphi-
philic substances. However, as previously mentioned, the 
main feature that makes PEO-PE micelles attractive for 
diagnostic imaging applications is their size. 
Trubetskoy and co-workers (1996) incorporated 
amphiphilic chelating probes Gd(111In)-DTPA-PE and 
111In-DTPA into PEO-PE micelles (20 nm in diameter) 
and tried to use these particulate agents in experimental 
percutaneous lymphography using gamma-scintigraphy 
and MRI in rabbits. Subcutaneous doses of 20 µCi ad-
ministrated into the dorsum of a rabbit hind paw and into 
the popliteal lymph node (first lymph node draining the 
injection site) were visualized within seconds of injection. 
The findings were compared to the control 111In-PEO-
liposomes (200 nm in diameter). Constituting small par-
ticles, micelles exhibit higher accumulation in the primary 
lymph node. Thus, the micellar particulates, due to their 
size and surface properties, can be moved easily from the 
injection site. Another experiment in the same study, using 
MRI of the axillary/subscapular lymph node area in rabbit, 
obtained after subcutaneous injection of small doses of 
Gd-DTPA-PE/PEO-PE micelles, showed that the collect-
ing lymph vessel and axillary lymph node become visible 
only 4 min after administration of Gd-containing micelles. 
Considering the ease and speed with which the 
primary lymph nodes may be visualized, the authors 
(Trubetskoy et al., 1999) suggested that polymeric mi-
celles are lymphangiographic in nature, unlike the other 
lymphotropic contrast media. The action of polymeric 
micelles is based upon the visualization of lymph flowing 
through different elements of the lymphatics whereas the 
other lymphotropic contrast media act based primarily on 
their active uptake by the nodal macrophages. In this case, 
lymph nodes become visible only after the concentration 
of the medium in the lymph node has reached a certain 
threshold value which usually requires prolonged periods 
of time (Torchilin, 2002).
DTPA is the most popular chelating agent for 
diagnostic heavy metals. Chelated paramagnetic metal 
moieties are of a hydrophilic nature and should acquire 
an amphiphilic nature in order to be incorporated into 
micelles (Torchilin, 2002). Several chelating probes of 
amphiphilic character were developed for liposome mem-
brane incorporation studies (Unger et al., 1994; Grant, 
Karlik, Florio, 1989) and probably can also be used for 
micelle incorporation, such as the conjugate agent PE-
DTPA. In these agents, the hydrophilic chelating residue 
is covalently linked to a hydrophobic lipid chain. The lipid 
part of the molecule is anchored in the polymeric micelle’s 
hydrophobic core (for example, PEO-PE), while the hy-
drophilic part containing the chelating moiety is located 
on the micelle hydrophilic polymer shell (surface), as 
illustrated in Figure 2 (Torchilin, 2002).
POLYMERIC MICELLES FOR DIAGNOSIS 
AND CANCER THERAPY
Cancer has been one of the major social and health 
concerns of the last ten decades. The use of nuclear medi-
cine applications in oncology is of particular importance as 
FIGURE 2 - Schematic representation of PEO-PE polymeric micelle formation labeled with 99mTc. Micelle is formed spontaneously 
in aqueous media by self-assembled amphiphilic polymers, such as PEO-PE units (the soluble and insoluble blocks are light blue 
and brown, respectively). The radioactive compound (yellow spheres) is incorporated into the micelle through the amphiphilic 
polychelating agent, PE-DTPA (dark blue).
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a rapidly developing therapeutic and diagnostic multimo-
dality. The investigation of novel specific tumor-targeting 
radiopharmaceuticals is currently a potential field of 
interest for both cancer imaging (tumor scintigraphy, for 
example) and/or therapy (Hamoudeh et al., 2008).
Radiopharmaceuticals are dosage forms consisting 
of a carrier and a trace amount of a radionuclide, which 
has a defined radiation type(s). Hence, the efficacy of a ra-
diopharmaceutical is determined by these two components 
(Hamoudeh et al., 2008; Grallert, Araujo, Tavares, 2003; 
Yokoyama et al., 1996). In tumor therapy, the therapeutic 
effect is due to the tumoral absorption of alpha (a) or beta 
(b) radiation energy emitted by the radionuclide. As men-
tioned earlier, the ideal radiopharmaceutical should carry 
the radionuclide quantitatively to the tumor tissue with no 
radiation reaching normal tissues. Addressing this need, 
current progress in the pharmaceutical nanotechnology 
field has been exploiting the development of promising 
approaches for designing novel nano- and micro-carriers 
able to deliver radionuclides in a selective manner to im-
prove the outcome of treatment and quality of diagnosis 
(Panchapakesan, Wickstrom, 2007).
The incorporation of anticancer agents into 
nanoparticulate or microparticulate carriers can be 
considered a useful means for controlling the tissular 
and cellular distribution profiles of these agents. This 
rational approach combines a controlled-release drug 
with targeted delivery in order to provide more efficient 
and less harmful solutions that overcome conventional 
chemotherapy limitations (Gu et al., 2007; Brigger, Du-
bernet, Couvreur, 2002).
Moreover, combining the more recent nuclear imag-
ing multimodalities, which provide high sensitivity and 
anatomical resolution such as PET/CT and SPECT/CT, 
with the use of specific tumor-targeting radiopharmaceu-
ticals, constitutes a promising strategy that will allow for 
earlier tumor detection, better treatment planning and more 
effective therapy, in the near future (Jain, Patravale, 2009; 
Pan et al., 2009; Hamoudeh et al., 2008).
Many polymeric micelle types have been proposed 
as carriers for anticancer therapeutic and diagnostic agents 
including paclitaxel (Zhang, Jackson, Burt, 1996), doxo-
rubicine (Yokoyama et al., 1990), cisplatin (Yokoyama et 
al., 1996) and Gd-DTPA (Trubetskoy et al., 1996). The 
use of micelles as possible carriers for tumor imaging 
agents involves the following factors: (i) the incorpora-
tion of gamma emitters such as 111In or 99mTc for gamma 
scintigraphy (Reddy, Sharma, Murthy, 2006; Trubetskoy, 
Torchilin, 1996); (ii) the incorporation of paramagnetic 
gadolinium complexes for MRI application (Kabalka, 
1989; Torchilin, 1994); and, (iii) X-ray computed to-
mography using iodine-containing polymeric micelles 
(Torchilin, Frank-Kamenetsky, Wolf, 1999; Trubetskoy 
et al., 1997).
An application of polymeric micelles as tumor 
imaging agents was reported by Torchilin (2002). 
PEO-PE-DTPA immunomicelles labeled with 111In and 
attached to a 2C5-antibody against Murine Lewis lung 
carcinoma (LLC) have been used to image the LCC. 
A micelle intra-tumoral accumulation enhancement of 
30% was observed for immunomicelles in comparison 
to unmodified micelles. It is noteworthy that to date, no 
studies on tumor targeted radiotherapy by micelles have 
been reported in the literature.
MOLECULAR MODELLING AND 
CADD APPLIED TO DEVELOPMENT OF 
RADIOPHARMACEUTICALS
The role of CADD in the pipeline of drug discovery, 
including radiopharmaceuticals, is accelerating the discov-
ery of new lead compounds and their structure optimiza-
tion for the pharmacological tests that follow (Salvadori, 
2008; Veselovsky, Ivanov, 2003). The main directions in 
CADD are based upon the availability of the experimen-
tally determined three-dimensional (3D) structure of the 
target macromolecule. If the target 3D structure is known, 
the methods of structure-based drug design (SBDD) are 
used. SBDD is perhaps the most elegant approach for dis-
covering compounds exhibiting specificity and efficacy. 
Otherwise, when the target 3D structure is not available, 
the indirect methods of CADD based upon the 3D struc-
tures of known ligands (ligand-based drug design, LBDD) 
are performed (Leach, 2001; Veselovsky, Ivanov, 2003; 
Salvadori, 2008; Wermuth, 2008).
CADD or CAMD (Computer-Aided Molecular 
Design) can provide the 3D structure of a molecule, its 
chemical and physical characteristics, comparisons of 
structures of different molecules, and visualization of 
complexes formed between them. Additionally, predic-
tions may be made about how related new molecules 
may function. Thus, the combination of quantum and/or 
molecular mechanics and also formalisms of quantita-
tive structure-activity relationships (QSAR) constitutes 
a formidable arsenal for rationally designing novel thera-
peutic and diagnostic agents. The molecular modeling 
approaches are tools of CADD and can provide electronic 
and thermodynamic data which are not available from 
X-ray crystallographic data, for example. Indeed, these 
formalisms are not confined to radiopharmaceuticals de-
velopment and can equally aid the development of contrast 
agents for imaging tissues, organs and tumors (Boudreau, 
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Efrange, 1992). Here, the applications of molecular mod-
eling methods were investigated in radiopharmaceuticals 
containing peptide derivatives as a bioactive agent. 
Classes of radiopharmaceuticals are being distin-
guished according to the applied design strategy. “Metal 
essential or first generation agents” are typically relatively 
small complexes in which the radioactive metal center 
is chelated with oxygen, sulfur, nitrogen or phosphorus 
atoms containing ligands which can be further functional-
ized with additional groups, such as the tissue-selective 
heart imaging agent Cardiolite® (99mTcMIBI6+; MIBI: 
1-isocyano-2-methoxy-methylpropane). The molecular 
parameters including size, charge state and solvation 
properties (hydrophilicity/lipophilicity) seems to be 
among the key factors governing the tissue-specific accu-
mulation of first generation agents. Heart specific agents 
might be characterized by lipophilicity and unipositive 
charge whereas brain specific agents are mostly neutral 
and moderately lipophilic. “Conjugate or second genera-
tion agents” are increasing in specificity and the complex 
containing the radioactive nucleus is covalently linked to 
a monoclonal antibody or a biologically active molecule 
which binds to specific receptor sites. A similar approach 
led to the development of “integrated or third generation 
agents” in which the outer sphere of the chelating ligand 
contains the sites for receptor binding, meaning the ligand 
itself mimics a biologically active molecule, for example, 
a steroid hormone such as estradiol or testosterone (Dil-
worth, Parrott, 1998; Guidoni et al., 2002).
Reichert and Welch (2001) reported applications 
of molecular mechanics methodologies to metal-based 
imaging agents. They developed parameters for a commer-
cially available modeling package capable of reproducing 
experimentally determined structures, such as octahedral 
Ga(III) and In(III), Tc(V) mono-oxo complexes, and 
Gd(III). Also, they discussed the use of a technique known 
as the coordination scan which allows the determination 
of the sterically preferred coordination state of a metal in 
a given metal-ligand complex. 
This seems to be useful for the prediction of in vivo 
stability. If the metal coordinated by a particular ligand pos-
sesses vacant coordination sites, it frequently displays low 
in vivo stability. This application can be particularly valu-
able in understanding the behavior of Gd-based MRI agents.
A common technique in the design of targeted radio-
pharmaceuticals is the use of bifunctional chelates which 
are conjugated to a previously developed substrate for the 
receptor of interest. Molecular modeling is of great utility 
in addressing the question of whether this modification 
to the substrate will have a negative impact on receptor 
binding. Considering this, Reichert and Welch (2001) also 
carried out molecular modeling studies of bifunctional 
chelate peptide conjugates. These authors developed pa-
rameters for In(III) and Cu(II) for the AMBER force field 
using automated procedures from a combination of crys-
tallographic structures and ab initio calculations. The new 
parameters produced resulted in good agreement with the 
experimental data. Subsequently, these were used to exam-
ine the conformational effects caused by the conjugation of 
111In-DTPA to the cyclic octapeptide octreotide, the widely 
used imaging agent OctreoScan (72), and the conjugation 
of 64Cu-DOTA (DOTA = 1,4,7,10-tetraazacyclododec-
ane-1,4,7,10-tetraacetic acid) to the parent peptide (the 
somatostatin (SST) analogue octreotide, sandostatin) 
(Figure 3). The 111In-OctreScan was the first diagnostic 
radiopeptide approved by the FDA for scintigraphy of 
patients with neuroendocrine tumors (Okarvi, 2008). The 
recent introduction of the metal chelator DOTA (Figure 4) 
considerably improved the stability of the radioconjugates, 
allowing incorporation of a variety of radionuclides for 
applications from receptor-mediated radionuclide therapy 
to PET (Froidevaux, Eberle, 2002).
The higher expression of peptide receptors in many 
tumor cells compared with normal tissues accelerated the 
development of radiolabeled small peptides for diagnostic 
imaging and radionuclide therapy in nuclear oncology 
where these receptors are considered potential molecular 
targets (see Figure 5) (Okarvi, 2008). Many naturally oc-
curring peptides exhibit extremely high affinities (nano- or 
subnano-molar range) for cell-surface receptors. The suc-
cessful development of new radiolabeled receptor-binding 
peptide analogues is dependent upon the molecular modi-
fications of a given natural peptide, preserving the original 
binding affinity for the target receptors. A few of these 
peptides, such as SST, bombesin, cholecystokinin/gastrin, 
neurotensin and vasoactive intestinal peptide are currently 
under investigation for their possible clinical applications 
in nuclear oncology (Okarvi, 2008).
Nikiforovich and co-workers (2007) applied molec-
ular modeling methodologies to a set of SST analogues for 
suggesting conformational scaffolds specifically targeting 
five subtypes of SST receptors (SSTRs, SSTR1 to SSTR5), 
which are overexpressed in gastroenteropancreatic, pitu-
itary and carcinoid tumors, for example.
Most tumors exhibit overexpression of SSTR2 
(breast cancer, carcinoid, neuroblastoma, etc.). SSTR5 
overexpression is also present in growth hormone 
(GH)-expressing pituitary adenoma and kidney cancer. 
SSTR4 is overexpressed in ovary cancer whereas SSTR1, 
SSTR2, SSTR3 and SSTR5, simultaneously, are all over-
expressed in thyroid cancer (Reubi, 2003; Froidevaux, 
Eberle, 2002).
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The authors (Nikiforovich, Marshal, Archilefu, 
2007) compared the low-energy backbone structures of 
the investigated peptides and suggested unique confor-
mations of the central fragment (Phe/Ala-DTrp-Lys-Thr) 
characteristic of specific interactions of SST with each of 
the five distinct subtypes of SSTRs.
The resulting conformations were in good agree-
ment with experimental data obtained earlier by NMR 
measurements and/or X-ray crystallography, and may 
serve as conformational templates for rational design of 
non-peptide scaffolds which effectively and selectively 
interact with different SSTRs subtypes.
Bombesin (BN) is a 14-amino acid neuropeptide 
(Figure 6) which shows high affinity for the human gas-
trin-releasing peptide (GRP) receptor overexpressed by 
a variety of cancers, including prostate, breast, pancreas, 
gastrointestinal, and small cell lung cancer (Okarvi, 2004; 
Reubi, 2003). High expression of BN/GRP receptors in 
various tumors provides an attractive target for BN/GRP 
receptor scintigraphy and radionuclide therapy (Fleish-
mann et al., 2005; Okarvi, 2004).
The C-terminal 7-14 amino acid sequence (Gln-
Trp-Ala-Val-Gly-His-Leu-Met-NH2) of BN-like peptides 
is known to be critical for receptor binding affinity and 
biological activity (Smith, Volkert, Hoffman, 2005). Most 
radiolabeled BN-like peptides are based on the 7-14 amino 
acid sequence, coupled with a chelator through a spacer 
group at the N-terminus of the peptide (Smith, Volkert, 
Hoffman, 2005; Okarvi, 2004). Also, much attention has 
been focused on developing 99mTc-labeled BN-like pep-
FIGURE 3 - Amino acid residue sequences for SST-14 and 111In-OctreoScan (adapted from Okarvi, 2008), and the 3D structure 
of sandostatin retrieved from PDB entry code 1SOC (Melacini, 1997). The hydrogen atoms not shown in the 3D-model. Carbon 
atoms are shown in light blue, nitrogen in dark blue, oxygen in red, and sulfur in yellow.
FIGURE 4 - Chemical structure of DOTA and its respective 
3D-model extracted from PDB entry code 1NC4 (Corneillie, 
Fischer, Meares, 2003). The hydrogen atoms are not displayed 
in the 3D-model. Carbon atoms are shown in light blue, nitrogen 
in dark blue and oxygen in red.
FIGURE 5 - Schematic representation of strategy to target 
receptor with peptide radiopharmaceutical (Adapted from 
Okarvi, 2008).
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tides with different types of chelators, peptide sequences 
and spacer groups (Okarvi, 2004). Araújo and co-workers 
(2009) submitted an innovative project on molecular 
labeled radionuclide BN derivatives for diagnosis and 
therapy of tumors which overexpress GRP receptors to 
the National Institute of Industrial Property (Instituto Na-
cional da Propriedade Industrial, INPI) requesting patent 
reservation (Araujo, Pujatti, Grallert, 2009). Currently, 
experimental and molecular modeling studies of a set of 
promising BN-like peptides as novel radiopharmaceuticals 
have been performed by researchers from the Center for 
Radiopharmacy at the Institute of Nuclear and Energy 
Research (Instituto de Pesquisas Energéticas e Nucleares, 
IPEN-CNEN/SP) in partnership with researchers from 
the Research Laboratory of Design and Development of 
Drugs (Laboratório de Planejamento e Desenvolvimento 
de Fármacos, LPDF - Faculty of Pharmaceutical Sciences, 
University of Sao Paulo). 
RECENT STUDIES IN BRAZILIAN 
INSTITUTIONS
The Institute of Nuclear and Energy Research 
(IPEN/SP), which is linked to the State of Sao Paulo Sec-
retary of Science, Technology and Economic Development 
and managed technically, administratively and financially 
by the National Commission of Nuclear Energy (Comissão 
FIGURE 6 - Amino acid residue sequence for BN-14 (Okarvi, 2008) and BN 3D-model selected from molecular dynamics simulation 
of 100 ps at 310 K. The hydrogen atoms not shown. Carbon atoms shown in light blue, nitrogen in dark blue, oxygen in red, and 
sulfur in yellow.
Nacional de Energia Nuclear, CNEN), holds the produc-
tion monopoly of radiopharmaceuticals labeled with radio-
isotopes of long half-life and also supplies several prod-
ucts nationwide, such as primary radioisotopes, labeled 
compounds, and lyophilized reagents ready to be labeled 
with 99mTc. The IPEN’s main facilities include a nuclear 
research reactor and a 30 MeV cyclotron for producing 
radioisotopes for use in medicine, industry and research.
The development of radiopharmaceuticals for detec-
tion of SLN demands prior investment in multiple centers 
bearing automated technology and quality control for 
producing positron-emitting radionuclides of short or ultra-
short half-life, such as 11C, 13N or 18F. Therefore, the use of 
PET modality for SLN imaging is not yet a reality in Brazil.
However, PET imaging technology is already imple-
mented in several hospitals and clinics in Sao Paulo city 
and, to a lesser extent, in nuclear medicine facilities in 
other regions of the country for the diagnosis of specific 
tumors, employing (18F)-2-fluoro-2-deoxyglucose (18F-
FDG) as the radiopharmaceutical.
The 18F has a relatively long half-life (110 minutes) 
in comparison to the other PET radionuclides outlined 
above. Thus, it can be produced at a regional centre, for 
example, and be distributed to local hospitals whereas 
other radionuclides need to be produced on site (84).
Alternatively, SPECT is a technique widely used 
and gamma-emitting radioisotopes, such as 99mTc and 123I, 
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labeling molecules with potential characteristics as radio-
tracers for mapping the lymphatic system are routinely 
produced by IPEN.
From this perspective, the development of a meth-
odology for preparation of polymeric micelles labeled 
with 99mTc would render radiochemical and biological 
investigations feasible, which are necessary for the design 
of a novel radiopharmaceutical with potential clinical 
application in diagnostic nuclear medicine. The research 
group of the Laboratory of Design and Development of 
Drugs (Laboratório de Planejamento e Desenvolvimento 
de Fármacos, LPDF - Faculty of Pharmaceutical Sciences, 
University of Sao Paulo) in partnership with the Center 
for Radiopharmacy (IPEN-CNEN) has developed a new 
radiopharmaceutical containing mixed polymeric micelles 
of PEO-PE-99mTc while important results using the scin-
tigraphy imaging modality in New Zealand rabbits were 
obtained regarding the visualization of lymphatic paths 
and SLN. Based upon these results and considering that 
this research area is still a restricted field in Brazil, the au-
thors submitted the new compound to the INPI requesting 
patent reservation.
CONCLUSION
Polymeric micelles composed of copolymers rep-
resent a promising class for diagnostic nuclear medicine. 
Radioisotopes as well as paramagnetic metals can be eas-
ily attached to the hydrophilic portions or non-covalently 
incorporated into the hydrophobic core. These copolymers 
spontaneously form colloidal particulates in aqueous 
solution, which measure from 10 to 100 nm in diameter 
depending on the molecular weight of the polymer block.
Polymeric micelles in particular have an excellent 
ability to solubilize poorly water-soluble drugs in vivo 
and increase their bioavailability. Moreover, the reduced 
particle size confers them efficient accumulation in areas 
of the body with low permeability and also areas of com-
promised vasculature.
Although this research field is relatively new, some 
approaches involving the application of polymeric mi-
celles as carriers of radiopharmaceuticals, radioisotopes, 
and contrast agents, for diagnostic/imaging use in nuclear 
medicine employing PEO and PE polymers labeled with 
111In or 99mTc, preferably, have shown promising results 
especially for SLN imaging, visualization of lymphatic 
pathways and diagnosis of some types of tumors, such as 
breast and prostate cancers.
Small peptides continue to play an important role 
in the diagnosis and treatment of cancers. The increasing 
evidence of peptide receptor overexpression in several 
human cancers serves as a trigger for the development of 
peptides for selective in vivo targeting of these tumors. In 
this sense, the application of molecular modeling meth-
odologies and some CADD strategies can be extremely 
useful for providing information that aids the rational 
design and development of novel radiopharmaceuticals.
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